Drug Profile
SAR 102779
Alternative Names: SAR 10279; SAR102779Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antidepressants; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Neurokinin 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Irritable bowel syndrome; Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in European Union
- 16 Jul 2016 No recent reports of development identified for phase-I development in Major depressive disorder in European Union